Gastrointestinal (Colorectal and Anal)
GASTROINTESTINAL CANCER—COLORECTAL AND ANAL 3500 Oral Abstract Session Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Thierry Andre, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J. A. Punt, Denis Michel Smith, Rocio Garcia-Carbonero, Julia Alcaide, Peter Gibbs, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Luis A. Diaz; Sorbonne Universite� and Ho^pital- Saint Antoine, Paris, France; University College Hospital, NHS Foundation Trust, London, United King- dom; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Herlev and Gentofte Hospital, Herlev, Denmark; University Hospital of Southern Denmark, Vejle, Denmark; Depart- ment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; Bordeaux University Hospital, Bordeaux, France; Hospital Universitario 12 de Octubre, Imas12, CNIO, UCM, Madrid, Spain; Hospital Regional Universitario de Malaga, Ma�laga, Spain; Western Health, St. Al- bans, Australia; Centre Le�on Be�rard, Lyon, France; Hospital Universitario Marque�s de Valdecilla, IDIV- AL, Santander, Spain; Vall dHebron Institute of Oncology, Barcelona, Spain; Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; National Cancer Center Hospital East, Kashiwa, Japan; MSD China, Shanghai, China; Merck & Co., Inc., Kenilworth, NJ; Memorial Sloan Kettering Cancer Center, New York, NY Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pem- brolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at second interim analysis (IA2) in patients (pts) with MSI-H/dMMR mCRC.
[Show full text]